Overview

* Biohaven ( BHVN ) reports Q3 net loss of $173.4 mln, operating expenses at $169.4 mln

* Company initiates strategic cost optimization to reduce annual direct R&D spend by 60%

* Biohaven ( BHVN ) focuses resources on late-stage programs for epilepsy, depression, and immune diseases

Outlook

* Biohaven ( BHVN ) expects top-line results from Opakalim Phase 2 study in depression in 4Q 2025

* Company plans to initiate Phase 2 trial for Taldefgrobep alfa in obesity in 4Q 2025

* Biohaven ( BHVN ) aims to reduce annual direct R&D spend by approximately 60%

Result Drivers

* COST OPTIMIZATION - Biohaven ( BHVN ) initiated strategic cost optimization to focus on late-stage clinical programs

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Net -$173.44

Income mln

Q3 Basic -$1.64

EPS

Q3 $169.38

Operatin mln

g

Expenses

Q3 -$169.38

Profit mln

From

Operatio

ns

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 15 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Biohaven Ltd ( BHVN ) is $27.00, about 69.4% above its November 7 closing price of $8.26

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)